[PDF][PDF] 6-[Fluorine-18] fluorodopamine pharmacokinetics and dosimetry in humans

DS Goldstein, L Coronado, IJ Kopin - Journal of Nuclear Medicine, 1994 - Soc Nuclear Med
6-[Fluorine- 18]Fluorodop amine Page 1 metabolized similarly to [3H]NE during sympathetic
stim ulation. Previous dosimetric estimates after [â€8F]-6F-DAinjec tion relied on studies of …

[PDF][PDF] Dosimetric estimates for clinical positron emission tomographic scanning after injection of [18F]-6-fluorodopamine

DS Goldstein, PC Chang, CB Smith… - Journal of Nuclear …, 1991 - Soc Nuclear Med
MATERIALS AND METhODS Studies of Rats Thirty male Sprague-Dawley rats weighing
351 ±(scm) 2.8 g underwent insertion of heparinized polyethylene cathe ters (internal …

Pharmacokinetics and radiation dosimetry of 18F-fluorocholine

TR DeGrado, RE Reiman, DT Price… - Journal of Nuclear …, 2002 - Soc Nuclear Med
18F-Fluorocholine (fluoromethyl-dimethyl-2-hydroxyethylammonium [FCH]) has been
developed as an oncologic probe for PET. This study evaluates the kinetics and radiation …

18F-fluorocholine: a new oncologic PET tracer

T Hara - Journal of Nuclear Medicine, 2001 - Soc Nuclear Med
Although considerable progress has been made using 18F-FDG in PET oncologic imaging,
there are some well-known limitations to its use. These include the inability of FDG to …

Novel electrophilic synthesis of 6-[18F]fluorodopamine and comprehensive biological evaluation

O Eskola, TJ Grönroos, A Naum, P Marjamäki… - European journal of …, 2012 - Springer
Abstract Purpose 6-[18 F] Fluorodopamine (4-(2-aminoethyl)-5-[18 F] fluorobenzene-1, 2-
diol, 6-[18 F] FDA) is a tracer for imaging sympathetically innervated tissues. Previous …

Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)?

GL Stöcklin - European journal of nuclear medicine, 1998 - europepmc.org
Merely, asking this question, which as posed by the Editor-in-Chief, implies that it cannon
easily be answered with a simple yes or no. in fact, it is closely related to the question, Is …

[PDF][PDF] Routine synthesis of L-[18F] 6-fluorodopa with fluorine-18 acetyl hypofluorite

MJ Adam, TJ Ruth, JR Grierson… - Journal of nuclear …, 1986 - Soc Nuclear Med
The synthesisof L-[18F16-fluorodopa (2.4 — 10.6 mCi) was done by passinggaseous [18F]
acetyl hypofluoritethrougha solutionof L-methyl-N-acetyl-[/3-(3-methoxy-4-acetoxyphenyl)] …

Do the metabolites of 6-[F-18] fluoro-L-dopa and of [F-18] fluoro-meta-L-tyrosine contribute to the F-18 accumulation in the human brain?

G Firnau, R Chirakal, C Nahmias, ES Garnett - 1990 - inis.iaea.org
[en] The purpose of this study was to determine if the metabolites of 6-[F-18] fluoro-L-dopa (F-
dopa) and of [F-18] fluoro-meta-L-tyrosine (FmLtyr) contribute to the accumulation of fluorine …

[PDF][PDF] Comparison of high specific activity (−) and (+)-6-[18F] fluoronorepinephrine and 6-[18F] fluorodopamine in baboons: heart uptake, metabolism and the effect of …

YS Ding, JS Fowler, SL Dewey, J Logan… - Journal of Nuclear …, 1993 - Soc Nuclear Med
(10, 11). While other positron emitters labeled false neu rotransmitters such as [†8F] fluoro-
metaraminol (12— 14) and [†œC@ hydroxyephedrine (15, 16) have been used to …

Routine determination of [18F]-L-6-fluorodopa and its metabolites in blood plasma is essential for accurate positron emission tomography studies

GLY Chan, KA Hewitt, BD Pate, P Schofield, MJ Adam… - Life sciences, 1992 - Elsevier
A batch-contact alumina-extraction method has been used to separate [18 F]-L-6-fluorodopa
(FD) from its principal metabolite, 3-O-methyl-[18 F]-6-fluorodopa (3-OMe-FD), in arterial …